Cancer biomarkers are biological molecules created in response to cancer by tumor cells or human tissues, which are subsequently analyzed and examined as indicators of malignant activities in the body. Cancer biomarkers are widely employed in the detection and treatment of cancer patients. Biomarkers are employed in the follow-up surveillance and early diagnosis of suspected recurring disease in cancer patients who have had curative surgery. Furthermore, the use of molecular biomarkers as part of normal diagnostic testing is a constant advancement in cancer diagnosis. The utilization of DNA, RNA, microRNAs, and proteins in cancer detection involves molecular changes. Various governments are focusing their investments on cancer prevention and early intervention in order to decrease the emotional and physical effects of cancer on patients and their families.
Growing funding for research and development from various government and private organizations is propelling the cancer biomarkers market forward.
Increasing investment in Cancer Biomarkers Market and development is a priority for a number of government and corporate organizations. This is due to an increase in the global incidence and prevalence of cancer. For example, Cancer Research UK proposed funding of US$ 140,922 per year for a biomarker project to develop, validate, and qualify Cancer Biomarkers Market assays for use in cancer clinical diagnosis in June 2018. In addition, the National Cancer Institute (NCI) spent US$ 5.5 million in March 2016 to establish laboratories to perform research on biomarkers and biomarker tests for cancers of the breast, prostate, lung, and genitourinary organs, as well as cancers with a high incidence rate.
The Cancer Biomarkers Market is predicted to grow due to the high prevalence and incidence of cancer.
After skin cancer, breast cancer is the second most frequent type of cancer in the United States. Both men and women are susceptible to breast cancer. Breast cancer is more common in women than in men, and male breast cancer is extremely rare. According to the Centers for Disease Control and Prevention (CDC), 236,968 women and 2,141 men were diagnosed with breast cancer in the United States in 2014, with 41,211 women and 465 men dying from the disease.
BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc. are some of the major competitors in the cancer biomarkers market.
0 Comments